Tarceva May Improve Survival From Lung Cancer
Patients whose advanced lung cancers bear the EGFR mutation survive 2 to 3 times longer if given initial treatment with Tarceva.
Click here to read the full story.
No profanity or inappropriate comments will be allowed.
Offensive posters will be blocked from future postings.
The content has been reported and it will be reviewed by a moderator.
